Tuesday, 28 February 2017

Premenstrual Dysphoric Disorder Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020

ResearchMoz added Latest Research Report titled " Premenstrual Dysphoric Disorder Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020 " to it's Large Report database.

Premenstrual Dysphoric Disorder
(PMDD) is a severe condition in which most women develop depression, irritability and tension before menstruation. The U.S. Department of Health and Human Services stated that, premenstrual dysphoric disorder is more severe and serious compared to premenstrual syndrome (PMS). Exact cause for premenstrual dysphoric disorder is unknown however researchers demonstrated that few factors are associated with it that includes depression, vitamin deficiency, changes in hormone related to menstrual cycle, drinking alcohol and eating salty food. Possible signs and symptoms for premenstrual dysphoric disorder includes feeling sadness or hopelessness, fatigue or low energy, food cravings, panic attacks and change in appetite. Other symptoms of premenstrual dysphoric disorder can be sleep problems, difficulty in concentration and physical problems such as bloating, breast tenderness, swelling, headaches, joint or muscle pain.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=222453

Women with unhygienic lifestyle are at high risk for developing premenstrual dysphoric disorder. Currently no diagnosis test is available in the market for detection of premenstrual dysphoric disorder but sometimes psychiatric evaluation might be performed to rule out the other conditions associated with premenstrual dysphoric disorder. Treatment and management of premenstrual dysphoric disorder includes good nutrition, exercise and medication (Sarafem, Paxil CR, and Zoloft).

Increasing unhygienic lifestyle among women is considered as a major market driving factor for the global premenstrual dysphoric disorder treatment market because premenstrual dysphoric disorder is mostly seen among women with unhygienic lifestyle. Moreover, growing knowledge among women about premenstrual dysphoric disorder would further accentuate the market growth in few developing nations in the world. In addition, treatment products for premenstrual dysphoric disorder is easily available in almost all medical stores across the world are considered as a market driving factor for this market. However, lack of diagnostic tests available in the market for detection of premenstrual dysphoric disorder would restrict its demand in the global premenstrual dysphoric disorder treatment market.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

The U.S. National Library of Medicine stated that, premenstrual dysphoric disorder affects 3% to 8% of the U.S. women before they are having menstrual periods. Hence, North America and Europe dominates the global market for premenstrual dysphoric disorder treatment due to high prevalence rate of premenstrual dysphoric disorder in these regions. Moreover, favorable initiative taken by the federal government would also account for the market growth of the North American and European premenstrual dysphoric disorder market. In addition, strong demand of treatment product of premenstrual dysphoric disorder in North American and European regions is also accounted for the market growth in these regions. Asia-Pacific is considered as an untapped market due to lack of awareness among people in few of the remote areas in Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Rest of the world (RoW) holds fourth position in the global premenstrual dysphoric disorder treatment market due to poor economic and health condition in most of the African countries. 

Some of the major market players involved in manufacturing the treatment product of premenstrual dysphoric disorder and contributing the global market share includes Eli Lilly and Company, Endo Pharmaceuticals, Forest Laboratories, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline plc, Abbott Healthcare, Merck and Co., Cipla Laboratories, Novartis AG, Bristol Meyer Squibb, Dr. Reddy’s Laboratories Ltd. among others.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
  •     Market growth drivers
  •     Factors limiting market growth
  •     Current market trends
  •     Market structure
  •     Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

No comments:

Post a Comment